Knowledge Hub

Apolipoprotein E (APOE) - Pipeline Review, H2 2016

Press release   •   Nov 28, 2016 05:23 EST has recently announced the addition of a market study “ Apolipoprotein E (APOE) - Pipeline Review, H2 2016 ”, is a comparative analysis of the global market.

Apolipoprotein E (APOE) - Pipeline Review, H2 2016


Global Markets Directs, Apolipoprotein E (ApoE) - Pipeline Review, H2 2016, provides in depth analysis on Apolipoprotein E (ApoE) targeted pipeline therapeutics.

The report provides comprehensive information on the Apolipoprotein E (ApoE) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein E (ApoE) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Download The sample Copy Of This Report:


- The report provides a snapshot of the global therapeutic landscape for Apolipoprotein E (ApoE)

- The report reviews Apolipoprotein E (ApoE) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Apolipoprotein E (ApoE) targeted therapeutics and enlists all their major and minor projects

- The report assesses Apolipoprotein E (ApoE) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Apolipoprotein E (ApoE) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Apolipoprotein E (ApoE)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Apolipoprotein E (ApoE) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Content

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Apolipoprotein E (APOE) Overview 6

Therapeutics Development 7

Apolipoprotein E (APOE) - Products under Development by Stage of Development 7

Apolipoprotein E (APOE) - Products under Development by Therapy Area 8

Apolipoprotein E (APOE) - Products under Development by Indication 9

Apolipoprotein E (APOE) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Apolipoprotein E (APOE) - Products under Development by Companies 12

Apolipoprotein E (APOE) - Products under Development by Universities/Institutes 14

Apolipoprotein E (APOE) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 20

Apolipoprotein E (APOE) - Companies Involved in Therapeutics Development 22

LipimetiX Development Inc 22

Apolipoprotein E (APOE) - Drug Profiles 23

AEM-28 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

AEM-2802 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

AEM-2814 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Monoclonal Antibodies to Target ApoE for Alzheimer's Disease - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Recombinant ApoE4 for Dyslipidemia - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Activate ApoE for Alzheimer's Disease - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30